News
1h
Everyday Health on MSNZebound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
1hon MSN
“I’m down about 50 pounds. I want to lose another 50,” Barkley said, revealing he gained 100 pounds after hip surgery. The target weight, he said, is 270 pounds. He said he is taking Zepbound, a ...
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...
Explore more
Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
11h
InvestorsHub on MSNNovo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes TreatmentsNovo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...
Taking semaglutide and liraglutide — a lesser-known active ingredient — medications for weight loss cut their consumption by nearly two-thirds in just four months. At such a critical moment in US ...
Ozempic side effects are a hot topic but don’t panic – our experts are here to help. Here’s what to expect and how to ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results